ÃÍÁÏÊÓƵ

Register now to attend Clinical Congress on October 19–22 for education, networking, and the latest surgical innovation you won’t find anywhere else. Both in-person and virtual attendance options are available! Clinical Congress offers outstanding educational opportunities for every stage in your surgical career—all in one place.  

While at ACS Clinical Congress 2024, please attend the Cancer Programs session.  Click on the title link to add the session to your interactive program planner.

CAPS113.

October 20, 2024, 11:30 am–1:00 pm PT

Join the Cancer Programs panel session where we will clarify the recommendations and present the results of recent trials with their impact on neoadjuvant treatment and outcomes.

Objectives

1. Describe when to recommend surgery or neoadjuvant therapy for early stage HER2+ breast cancers.
2. Outline when to recommend surgery or neoadjuvant therapy for early stage triple negative breast cancers.
3. Discuss recent study data to support treatment pathways.

: Mediget Teshome, MD FACS

: Laurie J. Kirstein, MD FACS

PS208.

October 21, 2024, 9:45–11:15 am PT

Join the Cancer Programs panel session where we will provide updates on current practice and recent trials in the management of melanoma, including indications and role of sentinel node biopsy, the management of regional disease such as in-transit and lymphatic metastases, and indications for adjuvant therapy.

Objectives

1. Describe the indications for sentinel node biopsy in melanoma.
2. Outline the role of adjuvant therapy in the management of stage II and Ill melanoma.

: Bruce M. Brenner, MD FACS

: Virginia L. Shaffer, MD FACS

PS239.

October 21, 2024, 4:15–5:45 pm PT           

Join the Cancer Programs panel session where we will discuss the various total neoadjuvant therapy (TNT) and surveillance protocols and what these variations may mean in terms of patient care.

Objectives

1. Discuss the options for various TNT and surveillance protocols for rectal cancer.
2. Compare and contrast the benefits and downsides of watch and wait compared to total mesorectal excision (TME) resection.

: Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng,Ed), Hon FRCS (I,Gl)

Virginia L. Shaffer, MD FACS

PS236.

October 21, 2024, 4:15–5:45 pm PT           

Join the Cancer Programs panel session where we will provide updates on the most recent evidence-based information to help guide the interpretation, any necessary workup, patient discussion, and surgical management (if necessary) of the incidental pancreatic intraductal papillary mucinous neoplasm (IPMN), appendiceal, gallbladder, kidney, or adrenal lesion noted on abdominopelvic imaging.

Objectives

1. Describe the Epidemiology/incidence of each incidentaloma, including any 'special' populations.
2. Describe what, if any, action needs to be taken when the incidental pancreas, adrenal mass, or appendiceal mass is noted on imaging studies and more.

: Melanie R. Goldfarb, MD FACS

: Fabian M. Johnston, MD FACS

PS303.

October 22, 2024, 8:00–9:30 am PT           

Join the Cancer Programs panel session where we will discuss the rapidly changing management of Ductal Carcinoma In Situ (DCIS). In the latest retrospective literature, it now suggests that some cases of DCIS may be treated with observation or with de-escalation and soon the results of the Comparison of Operative to Monitoring and Endocrine Therapy for low-risk ductal carcinoma In Situ (COMET) trial will determine if observation of DCIS is safe in certain patients.

Objectives

1. Describe the natural history of DCIS.
2. Review the most recent results of retrospective data and prospective trials.
3. Outline the current management of DCIS.

: Catherine E. Pesce, MD FACS

: Rachel A. Greenup, MD FACS

PS313.

October 22, 2024, 9:45–11:15 am PT

Join the Cancer Programs panel session where we will discuss the recently published ACS Operative Standards in Cancer Surgery sections on adrenal cancer, neuroendocrine cancers of the gastrointestinal tract and pancreas, and thyroid cancer and we will review in detail the technical aspects of resection of these malignancies. A video demonstration will be included. Data from current key questions relevant to each malignancy will be presented.

Objectives

1. Attendees will be able to outline the technical steps necessary to perform adrenalectomy, resection of neuroendocrine cancers of the pancreas and gastrointestinal tract, and thyroid consistent with good oncologic practice.
2. Learners will understand the answers to key questions presented, rationale for recommendations made, and be able to incorporate presented data to support day-to-day clinical decision making and more..

: Barbra S. Miller, MD FACS

: Tracy S. Wang, MD FACS

ME301.

October 22, 2024, from 11:30 am–12:30 pm PT

Join the Cancer Programs meet the expert session where we will discuss how the National Accreditation Program for Rectal Cancer (NAPRC) was developed through a collaboration between the OSTRiCH (Optimizing the Surgical Treatment of Rectal Cancer) consortium and the Commission on Cancer (CoC), a quality program of the American College of Surgeons. The outcomes of rectal cancer have repeatedly been shown to be variable and highly contingent on specialization, training, and volume. The NAPRC aims to standardize and improve care using a multidisciplinary approach.

Objectives

1. Describe the purpose of the NAPRC and reasons for its existence.
2. Successfully prepare for an accreditation visit and more.

PS317.

October 22, 2024, 12:45–2:15 pm PT

Join the Cancer Programs panel session where we will review best practices for the diagnostic evaluation of pancreatic cysts, current evidence regarding the role of molecular analysis, surgical decision-making, and optimal surveillance strategies in asymptomatic, low-risk patients.

Objectives

1. Outline best practices in the diagnostic evaluation of pancreatic cystic neoplasms.
2. Discuss surgical decision-making and patient-selection in patients with cystic neoplasms of the pancreas.
3. Define optimal surveillance strategies in low-risk, asymptomatic patients with pancreatic cystic neoplasms.

: Rebecca Snyder, MD, FACS

: William Burns, MD, FACS

PS329.

 October 22, 2024, 2:30–4:00 pm PT          

Join the Cancer Programs panel session where we will provide a broad overview that highlights immunotherapy advances, new ways to measure and follow tumor burden, and novel forms of tumor ablation that avoid surgical removal. These concepts will be integrated into current management strategies for both common and unusual solid tumors. The cancers to be discussed include melanoma, colorectal cancer, thyroid cancer, and sarcomas.

Objectives

1. Develop an understanding of how new cancer treatments are decreasing the need for major surgical resections in melanoma.
2. Define which types of colorectal cancers, as characterized by genetic mutations, can be treated very effectively with immunotherapy.
3. Describe a novel technique for treating thyroid nodules and which patient populations are most suited for this procedure and more.

: Ronald P. DeMatteo, MD FACS

: Russell S. Berman, MD FACS